Vertex Pharmaceuticals Inc. (VRTX): price, analyst ratings, earnings and fundamentals
Updated 4 November 2026, 06:50 ET
Vertex Pharmaceuticals Inc. (VRTX) closed at $530.76 on 3 November 2026, down 4.0%. The stock is up 5.4% over one month and up 24.7% over one year. It trades 6.7% below its 52-week high of $568.67. Analysts recorded 14 actions in the last 90 days; the median price target of $608 is 14.6% above the last close. The company last reported on 2 November 2026 for Q3 2026: EPS of $4.76 against an estimate of $4.70, a beat of 1.3%, on revenue of $3.4 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open VRTX in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 14 analyst actions on VRTX from 10 firms: 12 maintained or reiterated a view and 2 initiations. Price targets were 12 raised and 1 lowered. The most recent targets from 14 firms range from $350 to $725, with a median of $608, 14.6% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 3 Nov 2026 | JP Morgan | Maintains Overweight | $560.00 to $570.00 |
| 3 Nov 2026 | Goldman Sachs | Maintains Buy | $654.00 to $725.00 |
| 3 Nov 2026 | Morgan Stanley | Maintains Overweight | $665.00 to $660.00 |
| 3 Nov 2026 | Scotiabank | Maintains Sector Outperform | $558.00 to $660.00 |
| 3 Nov 2026 | UBS | Maintains Buy | $615.00 to $640.00 |
| 3 Nov 2026 | TD Cowen | Maintains Buy | $550.00 to $575.00 |
| 3 Nov 2026 | Wells Fargo | Maintains Overweight | $550.00 to $650.00 |
| 3 Nov 2026 | RBC Capital | Maintains Outperform | $576.00 to $600.00 |
| 3 Nov 2026 | Stifel | Maintains Hold | $500.00 to $563.00 |
| 3 Nov 2026 | Cantor Fitzgerald | Maintains Overweight | $595.00 to $619.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 11 February 2027 after the close for Q4 2026, with EPS expected at $4.53 on revenue of $3.5 billion. Vertex Pharmaceuticals Inc. beat the EPS estimate in 6 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3 2026 | 2 Nov 2026 | $4.70 | $4.76 | +1.28% | $3.4B |
| Q2 2026 | 3 Aug 2026 | $4.63 | $4.73 | +2.16% | $3.3B |
| Q1 2026 | 4 May 2026 | $4.18 | $4.47 | +6.94% | $3.0B |
| Q4 2025 | 12 Feb 2026 | $4.85 | $5.03 | +3.71% | $3.2B |
| Q3 2025 | 3 Nov 2025 | $4.35 | $4.80 | +10.34% | $3.1B |
| Q2 2025 | 4 Aug 2025 | $4.05 | $4.52 | +11.88% | $3.0B |
| Q1 2025 | 5 May 2025 | $4.29 | $4.06 | -5.36% | $2.8B |
| Q4 2024 | 10 Feb 2025 | $4.02 | $3.98 | -1.00% | $2.9B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
For the period ended 30 September 2026, Vertex Pharmaceuticals Inc. reported revenue of $3.4 billion and net income of $653.6 million. On a trailing twelve month basis the company shows revenue growth of 10.48%, a gross margin of 85.53%, an operating margin of 33.23% and a return on equity of 20.80%.
Income statement
| Line | Amount |
|---|---|
| Revenue | $3,440,800,000 |
| Cost of Revenue | $526,100,000 |
| Gross Profit | $2,914,700,000 |
| Selling, General & Administrative Expenses | $844,100,000 |
| Depreciation & Amortization | $69,200,000 |
| Total Operating Expenses | $2,727,900,000 |
| Operating Profit | $712,900,000 |
| Interest Expense | $36,000,000 |
| Pre-tax Income | $783,400,000 |
| Income Tax Expense | $129,800,000 |
| Net Income | $653,600,000 |
Cash flow
| Line | Amount |
|---|---|
| Cash from Operating Activities | $643,100,000 |
| Stock-based Compensation | $174,400,000 |
| Cash from Investing Activities | -$6,100,600,000 |
| Capital Expenditures | $97,300,000 |
| Cash from Financing Activities | $4,296,900,000 |
| Share Repurchases | $126,700,000 |
| Free Cash Flow | $545,800,000 |
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $4,979,300,000 |
| Restricted Cash | $9,300,000 |
| Short-term Investments | $1,324,000,000 |
| Accounts & Notes Receivable, Net | $2,311,000,000 |
| Prepaid Expenses | $826,700,000 |
| Inventory | $2,245,300,000 |
| Other Current Assets | $110,900,000 |
| Total Current Assets | $11,686,300,000 |
| Operating Lease Right-of-Use Assets | $1,617,200,000 |
| Long-term Investments | $3,517,900,000 |
| Goodwill Intangible Assets, Net | $10,941,200,000 |
| Deferred Tax Asset | $3,397,700,000 |
| Other Long-term Assets | $1,309,300,000 |
| Total Assets | $32,736,300,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Accounts Payable & Accrued Expenses | $472,600,000 |
| Total Short-term Debt | $1,005,100,000 |
| Operating Lease Liabilities, Current | $77,300,000 |
| Other Current Liabilities | $293,000,000 |
| Total Current Liabilities | $5,000,300,000 |
| Long-term Debt | $4,496,600,000 |
| Operating Lease Liabilities, Long-term | $1,981,800,000 |
| Finance Lease Liabilities | $112,200,000 |
| Other Liabilities | $1,349,800,000 |
| Total Liabilities | $11,828,900,000 |
| Common Stock | $2,500,000 |
| Retained Earnings | $16,344,800,000 |
| Other Accumulated Comprehensive Income | $57,200,000 |
| Total Stockholders Equity | $20,907,400,000 |
| Total Liability & Stockholders Equity | $32,736,300,000 |
Figures as filed with the SEC for the period ended 30 September 2026, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 1.26 | 77th | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 2.34 | 73rd | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
| Quick Ratio | 1.72 | 76th | Calculated as the ratio of (Cash + Marketable Securities + Accounts Receivable) / Current Liabilities. The quick ratio is a measure of how well a company can meet its short-term financial liabilities. |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.14 | 61st | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.22 | 50th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Combined Leverage | 0.75 | 52nd | This ratio summarizes the combined effect that the degree of operating leverage (DOL) and the degree of financial leverage have on earnings per share (EPS), given a particular change in sales |
| Degree of Financial Leverage | 1.01 | 56th | Calculated as the ratio of Percentage change in EPS / Percentage change in EBIT. A higher degree of financial leverage means that the company has more volatile EPS. |
| Degree of Operational Leverage | 0.74 | 54th | Calculated as the ratio of Percentage change in EBIT / Percentage change in revenue. It is a measure of how earnings for the company is impacted by its sales activity. |
| Long Term Debt/Long Term Capital | 0.18 | 27th | Calculated as Long-Term Debt / (Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | 7.8% | 89th | The EBIT growth rate over the trailing twelve months (TTM) |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Free Cashflow Margin Pct | 24.7% | 87th | Calculated as the ratio of Free Cashflow from Operating Activities / Net Sales. It measures how much per dollar of revenue the company is able to convert into free cash flow. |
| Gross Margin Pct | 85.5% | 93rd | Calculated as the ratio of Revenue - Cost of Goods Sold (COGS) / Revenue. The gross margin represents the percent of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services sold by a company. |
| Operating Margin Pct | 33.2% | 91st | Calculated as the ratio of (Revenue - (Cost of Goods Sold + Labour + Sales, General & Administrative)) / Revenue. Operating margins are important because they measure efficiency. The higher the operating margin, the more profitable a company's core business is. |
| Operating Profit Pct Growth | 7.8% | 51st | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | 3.5% | 49th | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| Operating Profit Pct Growth 5 year CAGR (FY) | 10.2% | 66th | The Operating Profit compound annual growth rate (CAGR) over the past 5 years |
| PreTax Margin Pct | 36.7% | 91st | Calculated as the ratio of (Gross profit - (Operating Expense + Interest Expense)) / Revenue. The pretax profit margin enables profitability to be compared across companies with significant differences in size, scale, capital structure and tax rates. |
| Return on Assets Pct | 13.8% | 94th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 20.8% | 87th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
| Return on Invested Capital Pct | 15.2% | 83rd | Calculated as the ratio of (Net Income - Dividends) / (Debt + Equity). It is a measure of how efficient the company is at allocating the capital under its control to profitable investments. |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| FCF Pct Growth | -4.0% | 40th | The Free Cash Flow growth rate over the trailing twelve months (TTM) |
| FCF Pct Growth 3 year CAGR | -23.8% | 30th | The Free Cash Flow compound annual growth rate (CAGR) over the past 3 years |
| FCF Pct Growth 5 year CAGR | 66.9% | 61st | The Free Cash Flow compound annual growth rate (CAGR) over the past 5 years |
| FCF Return on Assets Pct | 11.1% | 86th | Calculated as the ratio of Cashflow from Operations / Total Assets. A high cash return on assets means a company is generating more cash flow from every asset dollar |
| Operating Cashflow Pct Growth | -0.6% | 44th | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | -5.5% | 34th | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 11.5% | 69th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | 8.2% | 49th | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | 4.6% | 53rd | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | 12.8% | 70th | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 10.5% | 62nd | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 10.3% | 66th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 12.7% | 68th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 16.5% | 60th | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open VRTX in FundSpec.
Insider activity
In the last 90 days insiders filed 6 transactions: 5 acquisitions covering 14,599 shares. Acquisitions include awards and option exercises as well as open market purchases. The largest by value was an acquisition of 795 shares by Daniel J. Brennan, Director on 20 October 2026, worth about $400,259 at the transaction price.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 20 Oct 2026 | Daniel J. Brennan | Director | Acquisition | 795 | $503.47 | $400K |
| 15 Oct 2026 | Bruce I Sachs | Director | Acquisition | 93 | $512.44 | $48K |
| 15 Oct 2026 | Alan M Garber | Director | Acquisition | 29 | $512.44 | $15K |
| 8 Sep 2026 | Grunsven Jasper Van | EVP, CP and NPPO | Acquisition | 8,682 | ||
| 28 Aug 2026 | Kristen Ambrose | SVP & Chief Accounting Officer | Acquisition | 5,000 | ||
| 27 Aug 2026 | Bruce I Sachs | Director | G | 6,000 | ||
| 21 Jul 2026 | Amit Sachdev | EVP Chief Patient & Ext Af Off | Acquisition | 8,251 | ||
| 21 Jul 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Acquisition | 8,251 | ||
| 15 Jul 2026 | Bruce I Sachs | Director | Acquisition | 100 | $475.28 | $47K |
| 15 Jul 2026 | Alan M Garber | Director | Acquisition | 32 | $475.28 | $15K |
| 2 Jul 2026 | Duncan Mckechnie | EVP, Chief Commercial Officer | S | 1,541 | $519.00 | $800K |
| 2 Jul 2026 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | S | 1,500 | $524.99 | $787K |
| 1 Jul 2026 | Joy Liu | EVP and Chief Legal Officer | S | 828 | $502.71 | $416K |
| 26 Jun 2026 | Carmen Bozic | EVP and CMO | S | 596 | $482.50 | $288K |
| 18 Jun 2026 | Carmen Bozic | EVP and CMO | S | 1,020 | $462.17 | $471K |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 10-Q from 3 November 2026.
| Filed | Form | Document |
|---|---|---|
| 3 Nov 2026 | 10-Q | View on sec.gov |
| 4 Aug 2026 | 10-Q | View on sec.gov |
| 5 May 2026 | 10-Q | View on sec.gov |
| 13 Feb 2026 | 10-K | View on sec.gov |
| 4 Nov 2025 | 10-Q | View on sec.gov |
| 5 Aug 2025 | 10-Q | View on sec.gov |
| 6 May 2025 | 10-Q | View on sec.gov |
| 13 Feb 2025 | 10-K | View on sec.gov |
| 5 Nov 2024 | 10-Q | View on sec.gov |
| 2 Aug 2024 | 10-Q | View on sec.gov |
Company profile
- Exchange
- Nasdaq
- Sector
- Pharmaceuticals, Biotech and Chemicals
- Industry
- Pharmaceutical Products
- Headquarters
- Boston, Massachusetts
- Chief executive
- Reshma Kewalramani
- Employees
- 4,800
- Website
- vrtx.com
- SEC CIK
- 0000875320
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Sector and peers
Vertex Pharmaceuticals Inc. is part of the Pharmaceuticals, Biotech and Chemicals sector, which FundSpec tracks across 610 companies.
Companies in the same industry by market capitalization:
LLY Eli Lilly & Co.JNJ Johnson & JohnsonABBV AbbVie Inc.MRK Merck & Co. Inc.NVS Novartis AGAZN AstraZeneca PLCABT Abbott LaboratoriesPFE Pfizer Inc.
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for VRTX are available to subscribers, with the same screen in the iOS and Android apps.
Open VRTX in FundSpec